

ASX ANNOUNCEMENT

19 December 2019

Australian-produced medicinal cannabis product ready for commercial release in early 2020

Highlights

Commercial cGMP product undergoing stability testing

First sales expected in first quarter of 2020

Important commercial milestone for both Cann Group and IDT

19 December 2019 - Cann Group Limited (ASX: CAN) and IDT Australia Limited (ASX: IDT) today jointly announced that the first commercial medicinal cannabis product to be produced from Cann Group's Australian-based cultivation operations has been packed by IDT under cGMP conditions and will undergo stability testing ahead of release in the first quarter of calendar year 2020.

Medicinal Cannabis Dried Flower has been packed into 10g bottles in IDT's licensed cGMP manufacturing facilities (pictured below) and stability testing data is due to be available at the end of January. This will clear the way for commercial launch by Cann Group to Australian patients early in 2020, who can access the product under the Special Access Scheme (SAS). Cann Group has a national distribution arrangement with Symbion Health which will ensure product is available via Symbion's extensive network of retail and hospital pharmacies. The product will also be available for potential export.

Cann Group and IDT have an agreement in place for IDT to provide cGMP manufacturing services and support to convert medicinal cannabis produced by Cann into cGMP grade Active Pharmaceutical Ingredients and product formulations for patients in Australia and overseas.

While this first commercial product will initially be utilised for Australian domestic requirements, Cann Group continues to develop export pathways. The Company recently completed its first export of Australian grown and packaged medicinal cannabis dry flower to Aurora Cannabis Inc. in Canada.

This initial export of product – which was cultivated by Cann Group at its Southern production and research facility in Melbourne and packaged and labelled under cGMP conditions by IDT will be used by Aurora for research purposes, but is an important validation of export pathways ahead of future commercial supply.

Cann Group CEO, Peter Crock, said the manufacturing of locally sourced product represents a significant milestone in the commercialisation phase of the business.

"IDT has demonstrated a clear capability to manufacture cGMP medicinal cannabis products. As Cann Group increases our cultivation and production capacity at the new Mildura facility, it is critical that we have the ability to efficiently convert that material into commercial formulations."

IDT's CEO, Dr David Sparling, said it is an important milestone for IDT to have completed an initial commercial manufacturing run of a cGMP medicinal cannabis product.

"IDT is creating a new chapter in its long history of secure and high containment specialty pharmaceutical product manufacture. The Company has the requisite licences in place; and equipment and processes necessary to convert large quantities of medicinal cannabis starting materials into a range of innovative cGMP pharmaceutical products."



IDT

Dr David Sparling
Chief Executive Officer
IDT Australia Limited
+61 303 9801 8888
dsparling@idtaus.com.au

About IDT

IDT (ASX:IDT) is a public Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. It has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Cann Group

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@cann grouplimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 498 000 762
clive.fanning@cann grouplimited.com

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia's first medicinal cannabis research licence in February 2017, in addition to Australia's first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – one of Canada's largest listed medicinal cannabis companies – is a cornerstone investor in Cann, with a 22.5% shareholding.